Generic Name and Formulations:
Tafluprost 0.0015%; oph soln; preservative-free.
Indications for ZIOPTAN:
For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
1 drop in conjunctival sac of affected eye(s) once daily in the PM.
Do not exceed recommended dose (may reduce efficacy). Active intraocular inflammation (eg, iritis/uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Pregnancy (Cat.C); use effective contraception. Nursing mothers.
Allow at least 5 minutes between application of other topical oph agents.
Conjunctival hyperemia, ocular stinging/irritation, ocular pruritus including allergic conjunctivitis, cataract, dry eye, ocular pain, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), other eyelash changes, blurred vision, macular edema, headache, cold, cough, urinary tract infection.
Single-use containers (0.3mL)—30, 90
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics